Portal de Periódicos da CAPES

High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome

1995; Springer Science+Business Media; Volume: 16; Issue: 6 Linguagem: Inglês

10.1007/bf02229327

1126-5442

Alessandro Ravasio, Marco Pasquinelli, B. Currò Dossi, W. Neri, Carlo Guidi, Massimiliano Gessaroli, F Rasi, Rita Fabbri, Giuliano Mazzini, GG. Rebucci, G. Padoan, C. Callegarini, Giulio Ciucci, AR. Guidi, Gaetano Facchini, M. Galeotti, Mario Casmiro, G. Bianchedi, M. R. Tola, Vittorio Govoni, Enrico Granieri, G Tralli, V. Tugnoli, Vittoria Mussuto, R. D’Alessandro, Maria Guarino, R. Baldrati, Silvia Laudadio, T. Sacquegna, Fabrizio Salvi, G. Ambrosetto, P. Sorgato, Vittoria Ferrari, M Gentilini, Antonio Colombo, E. Merelli, Vittorio Miele, Valentina Lolli, Michele Santangelo, L. Motti, Donata Guidetti, F. Solimè, Franco Granella, Giovanni Pavesi, Isabella Allegri, Luigia De Falco, A. Scaglioni, E. Montanari, Sue Cammarata, Vanessa Fadanelli Schoenardie Poli,

Nerve injury and regeneration

We report the effects of treatment with plasma-exchange (PE) and intravenous immune globulins (IVIg) in 36 out of 50 patients with Guillain-Barré syndrome (GBS) recruited by an incidence study in the Emilia-Romagna region of Italy. Comparison of the patients treated with PE and IVIg showed no significant differences in terms of effectiveness in improving the clinical course of GBS: at one month, respectively 11.1% and 25% had recovered, and 55.5% and 58.3% had improved by at least one grade. These results are in agreement with those of the Dutch GBS trial. No relapses were observed in either group. Moreover, our results showed no difference in clinical outcome at 1 and 3 months between the patients receiving only one therapy and those receiving two; a second cycle of therapy did not seem to improve the clinical course of the disease significantly. We conclude that PE and IVIg are both safe and effective therapies for GBS.